BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 30299492)

  • 1. AL amyloidosis: advances in diagnostics and treatment.
    Ryšavá R
    Nephrol Dial Transplant; 2019 Sep; 34(9):1460-1466. PubMed ID: 30299492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AL amyloidosis with renal involvement.
    Rysavá R
    Kidney Blood Press Res; 2007; 30(6):359-64. PubMed ID: 17851224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2024 Feb; 99(2):309-324. PubMed ID: 38095141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Heart transplantation and the subsequent treatment of AL amyloidosis].
    Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
    Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Light Chain Amyloidosis: an Update for Treatment].
    Shen KN; Li J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):910-4. PubMed ID: 26117060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Al amyloidosis.
    Desport E; Bridoux F; Sirac C; Delbes S; Bender S; Fernandez B; Quellard N; Lacombe C; Goujon JM; Lavergne D; Abraham J; Touchard G; Fermand JP; Jaccard A;
    Orphanet J Rare Dis; 2012 Aug; 7():54. PubMed ID: 22909024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2020 Jul; 95(7):848-860. PubMed ID: 32267020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
    Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
    J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
    Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
    Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis.
    Vaxman I; Gertz M
    Acta Haematol; 2019; 141(2):93-106. PubMed ID: 30650422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
    Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional Therapy for Amyloid Light-Chain Amyloidosis.
    Milani P; Palladini G
    Acta Haematol; 2020; 143(4):365-372. PubMed ID: 32353854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney and liver involvement in monoclonal light chain disorders.
    Pozzi C; Locatelli F
    Semin Nephrol; 2002 Jul; 22(4):319-30. PubMed ID: 12118397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2016 Sep; 91(9):947-56. PubMed ID: 27527836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.